In a parallel study published in the journal International Immunopharmacology, short-term thymus gland hormone treatment (5 or more days) dramatically reduced survival at the 28-day point but not 60-day mortality, presumably because treatment was not continued.
In recent times it has become evident that T-cells (white blood cells produced in the thymus gland) are superior to antibodies in providing long-term immunity against infectious disease. T-memory cells not only activate antibodies but are able to “completely suppress viral replication or completely eradicate the virus.”
Thymus gland hormone (thymosin-A1), an approved therapy for infectious diseases and cancer, is posed as “hope out of the box in the COVID-19 disaster.”
No comments:
Post a Comment